206 related articles for article (PubMed ID: 36869232)
1. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A; Cirillo A; Pomati G; Cortesi E; Rossi E; Schinzari G; Tortora G; Tomao S; Fiscon G; Farina L; Scagnoli S; Pisegna S; Ciurluini F; Chiavassa A; Amirhassankhani S; Ceccarelli F; Conti F; Di Filippo A; Zizzari IG; Napoletano C; Rughetti A; Nuti M; Mezi S; Marchetti P
Cancer Immunol Immunother; 2023 Jul; 72(7):2217-2231. PubMed ID: 36869232
[TBL] [Abstract][Full Text] [Related]
2. A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors.
Mezi S; Pomati G; Fiscon G; Amirhassankhani S; Zizzari IG; Napoletano C; Rughetti A; Rossi E; Schinzari G; Tortora G; Lanzetta G; D'Amati G; Nuti M; Santini D; Botticelli A
Front Immunol; 2023; 14():1199089. PubMed ID: 37483633
[TBL] [Abstract][Full Text] [Related]
3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
4. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
5. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
6. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
8. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
9. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
11. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
13. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
14. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Hsu ML; Murray JC; Psoter KJ; Zhang J; Barasa D; Brahmer JR; Ettinger DS; Forde PM; Hann CL; Lam VK; Levy B; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Anagnostou V; Naidoo J; Feliciano JL
Oncologist; 2022 Nov; 27(11):971-981. PubMed ID: 35972337
[TBL] [Abstract][Full Text] [Related]
16. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
17. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
Yamaguchi A; Saito Y; Narumi K; Furugen A; Takekuma Y; Shinagawa N; Shimizu Y; Dosaka-Akita H; Sugawara M; Kobayashi M
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1659-1666. PubMed ID: 36346501
[TBL] [Abstract][Full Text] [Related]
18. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]